Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 2013

View Archived Issues

Proof-of-concept demonstration of functional regeneration via stem-cell organ bud transplantation

to-BBB Holding presents promising phase I results for new oncolytic agent

Novel furin inhibitors patented

Axikin presents novel MAP3K19 inhibitors

Bayer discloses new TTK inhibitors for cancer

Lupin reports novel MEK inhibitors

Isis Pharmaceuticals reaches milestone in phase II study in spinal muscular atrophy

Synergy Pharmaceuticals begins phase II study of SP-333

KB-3944, a promising new drug for multiple sclerosis

Puma Biotechnology begins phase II trial of PB-272 in HER2 solid tumors

PharmAkea Therapeutics and Celgene to advance therapies for cancer and fibrotic disease

Targeting LINGO1, a promising therapeutic strategy for multiple sclerosis

Phase Ib/II study of Erivedge begins in relapsed/refractory AML and high-risk MDS

MRC Technology and Renishaw Diagnostics collaborate on diagnostics for infectious disease

MJFF grant supports Durin Technologies' blood test for Parkinson's disease

European submission to broaden label for Arzerra to include first-line CLL

Cognoptix demonstrates potential of Sapphire II eye test to identify patients with Alzheimer's

Astellas and Mitokyne establish R&D collaboration for mitochondria-related disorders

ETC and Debiopharm establish oncology research collaboration

PeptiDream and Ipsen expand collaboration

MorphoSys completes phase I/IIa study of MOR-208 in CLL

Amplimmune acquisition strengthens MedImmune's oncology pipeline

Safety and efficacy of INCB-039110 confirmed in patients with psoriasis

Axiron testosterone replacement therapy approved in Germany

Researchers present phase I results for the anti-IL-31 receptor antibody CIM-331

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...